SEC Form 4 · accession 0001742727-26-000002
Protalix BioTherapeutics, Inc. · PLX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Yaron Naos
Officer — Sr. VP & COO
Period of report
Sep 3, 2026
Accepted (ET)
Sep 4, 2026 · 6:00 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001006281
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F1 | $2.59 | Sep 3, 2026 | A | 112,000 | A | — | Sep 3, 2036 | Common Stock | 112,000 | 112,000 | D |
| Restricted Stock UnitsF3,F4 | — | Sep 3, 2026 | A | 56,000 | A | — | — | Common Stock | 56,000 | 56,000 | D |
Explanation of responses
- F1The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant.
- F2Does not include (i) options to purchase 60,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2028, (ii) options to purchase 122,656 shares of common stock at an exercise price equal to $3.59 per share that expire on August 11, 2030 (iii) options to purchase 340,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iv) options to purchase 100,000 shares of common stock at an exercise price equal to $1.10 per share that expire on September 23, 2034, and (v) options to purchase 50,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035.
- F3Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock.
- F4The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.